WHO approves Mpox vaccine for adolescents

The World Health Organization officially announced the approval of Bavarian Nordic’s mpox vaccine for adolescents aged 12 to 17 on Monday. This development targets a demographic group deemed highly susceptible to mpox outbreaks.

Mpox disease is a significant source of international concern, prompting accelerated efforts to secure vaccine options for vulnerable groups. The WHO approval represents a crucial step in the global health response strategy.

The decision to authorize use of the vaccine reflects its importance in controlling the spread of the disease among younger populations, considered particularly at risk in the event of an outbreak.

(With input from agencies.)